An update on nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors

Current Pain and Headache Reports

Volumn 9, Issue 6, 2005, Pages 377-389

  Williams, Gary W ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETODOLAC; ETORICOXIB; GASTROINTESTINAL AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; LISINOPRIL; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PARECOXIB; PLACEBO; PREDNISONE; PROTON PUMP INHIBITOR; ROFECOXIB; SULINDAC; VALDECOXIB;

ACUTE HEART INFARCTION; ARTERY THROMBOSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIGESTIVE SYSTEM ULCER; DISEASE MODEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSMENORRHEA; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; INFLAMMATION; LOW DRUG DOSE; LUNG EMBOLISM; MONOTHERAPY; OSTEOARTHRITIS; PAIN; PRESCRIPTION; REVIEW; RHEUMATOID ARTHRITIS; SUDDEN DEATH; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS;

EID: 28944455472     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-005-0017-4     Document Type: Review

References (71)

1. Fries JF, Williams CA, Bloch DA, et al.: Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Gastroenterology 1989, 96(suppl 2): 647-655.
2. Bresalier RS, Sandler RS, Quan H. et al.: Cardiovascular events associated with rofecoxib in a colorectral adenoma chemoprevention trial. N Engl J Med 2005, 352:1092-1102.
3. Solomon SD, McMurray JJV, Pfeffer MA, et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071-1080.
4. Nussmeier NA, Whelton AA, Brown MT, et al.: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005, 352:1081-1091.
5. www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4090M1_Final.htm. Accessed August 2, 2005.
6. Food and Drug Administration. http://www.fda.gov/cder/drug/infopage/COX2/NSAIDdecisionMemo.pdf. April 6, 2005. Accessed August 2, 2005.
7. Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998, 38:97-120.
8. Data on File, G.D. Searle and Co.
9. Williams GW, Ettlinger RE, Ruderman EM, et al.: Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized, controlled trial. J Clin Rheumatol 2000, 6:65-74.
10. Williams GW, Hubbard RC, Yu SS, et al.: Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. Clin Ther 2001, 23:213-227.
11. Simon LS, Weaver AL, Graham DY, et al.: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized, controlled trial. JAMA 1999, 282:1921-1928.
12. Makarowski W, Zhao WW, Bevirt T, Recker DP: Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage 2002, 10:290-296.
13. McKenna F, Borenstein D, Wendt H, et al.: Celecoxib versus diclofenac in the management of osteoarthritis of the knee: a placebo-controlled, randomised, double-blind comparison. Scand J Rheumatol 2001, 30:11-18.
14. Cannon GW, Caldwell JR, Holt P, et al.: Rofecoxib, a specific inhibitor of cyclooxygenase 2, with efficacy comparable with that of diclofenac sodium: results of a 1-year, randomized, clinical trial in patients with osteoarthritis of the hip and knee. Arthritis Rheum 2000, 43:978-987.
15. Goldstein JL, Silverstein FE, Agrawal NM, et al.: Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000, 95:1681-1690.
16. Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized, controlled trial. JAMA 2000, 284:1247-1255.
17. Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000, 343:1520-1528.
18. Arthritis Advisory Committee; http://www.fda.gov/ohrms/dockets/ac/03/briefing/ 3930B1_01_B-TNF.Briefing.pdf. March 4, 2003. Accessed August 2, 2005.
19. Rahme E, Bardou M, Dasqupta K, et al.: Gastrointestinal bleeding associated with concurrent utilization of selective COX-2 inhibitors and aspirin versus non-selective NSAIDs and aspirin. Ann Rheum Dis 2004, 63 (suppl 1):522s-523s.
20. Rahme E, Barkun AN, Adam V, et al.: Treatment costs to prevent or treat upper gastrointestinal adverse events associated with NSAIDs. Pharmacoepidemiol Drug Saf 2004, 13:233s-234s.
21. Goldstein JL, Eisen G, Lewis B: Abstract presented at American College of Rheumatology 67th Annual Meeting. Orlando: October 23-26, 2003.
22. Rahme E, Barcon A, Toubouti Y, et al.: Do proton pump inhibitors (PPI) infer additional gastorintesinal protection in patients given celecoxib? A retrospective cohort study. Gastroenterology 2005, 128(suppl2):A24.
23. Chan FK, Hung LC, Suen BY, et al.: Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002, 347:2104-2110.
24. Laine L, Connors LG, Reicin A, et al.: Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003, 124:288-292.
25. Wilcox CM, Alexander LN, Cotsonis GA, Clark WS: Nonsteroidal anti-inflammatory drugs are associated with both upper and lower gastrointestinal bleeding. Dig Dis Sci 1997, 42:990-997.
26. Allison MC, Howatson AG, Torrance CJ, et al.: Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med 1992, 327:749-754.
27. Goldstein JL, Eisen GM, Lewis B, et al.: Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005, 3:133-141.
28. Weil J, Colin-Jones D, Langman M, et al.: Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995, 310:827-830.
29. Chan FK, Ching JY, Hung LC, et al.: Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005, 352:238-244.
30. Whelton A, Fort JG, Puma JA, et al.: Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001, 8:85-95.
31. White WB, Kent J, Taylor A, et al.: Effect of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002, 39:929-934.
32. Merck & Co, Inc.: VIOXX (rofecoxib) package insert [Pamphlet]. West Point, PA: Merck & Co, Inc; 2001.
33. McAdam BF, Catella-Lawson F, Mardini IA, et al.: Systemic biosynthesis of prostacycline by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999, 96:272-277.
34. Cheng Y, Austin SC, Rocca B, et al.: Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002, 296:539-541.
35. Strand V, Hochberg MC: The risk of cardiovascular thrombotic events with COX-2 selective inhibitors. Arthritis Rheum 2002, 47:349-355.
36. US Food and Drug Administration: Rofecoxib prescribing information label change; April 2002.
37. Ray W, Stein C, Daugherty J, et al.: Cox-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002, 360:1071-1073.
38. White WB, Faich G, Borer JS, et al.: Cardiovascular thrombotic events in arthritis trials of the cyclooxygnease-2 inhibitor celecoxib. Am J Card 2003, 92:411-418.
39. Chenevard R, Harlimann D, Bechir M: Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003, 107:405-409.
40. Title LM, Giddens K, McInerney MM, et al.: Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol 2003, 42:1747-1753.
41. Walter MF, Jacob RF, Day CA, et al.: Sulfone COX-2 inhibitors increase susceptibility of human DL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 2004, 177:235-243.
42. Sotirios Tsimikas MD, Emmanouil S, Brilakis MD, et al.: Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005, 353:46-57.
43. Thun MJ, Henley SJ, Patrono C: Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002, 94:252-266.
44. Giovannucci E, Egan KM, Hunter DJ, et al.: Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995, 333:609-614.
45. Steinbach G, Lynch PM, Phillips RK, et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342:1946-1952.
46. Bresalier RS, Sandler RS, Quan H, et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092-1102.
47. Solomon SD, McMurray J, Pfeffer MA, Adenoma Prevention with Celecoxib Study Investigators, et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071-1080.
48. Levin B: FDA Advisory Committee Meeting. Gaithersburg, MD: February 17, 2005.
49. Ott E, Nussmeier NA, Duke PC, et al.: Efficacy and safety of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003, 125:1481-1492.
50. Nussmeier NA, Whelton AA, Brown MT, et al.: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005, 352:1081-1091.
51. Solomon DH, Schneeweiss S, Glynn R, et al.: Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004, 109:2068-2073.
52. Graham DJ, Campen DH, Cheetham C, et al.: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase-2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005, 365:475-481.
53. Sudbo J: Population-based, nested case-control study of 454 Scandinavian patients diagnosed with oral cancer between 1975 and 2003, and 454 gender- and age-matched controls. Presented at the American Association of Cancer Research Annual Meeting; 2005,
54. Johnsen SP, Larsson H, Tarone RE, et al.: Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005, 165:978-984.
55. White WB, Strand V, Roberts R, Whelton A: Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther 2004, 11:244-250.
56. Whelton A, Nussmeier NA, Martineau RJ, et al.: Safety of parecoxib and valdecoxib in the treatment of postoperative pain following coronary artery bypass graft surgery or major general surgery. Presented at American College of Cardiology Annual Scientific Session. Orlando: March 6-9, 2005.
57. Pearson TA, Blair SN, Daniels SR, et al.: AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002, 106:388-391.
58. Lévesque LE, Brophy JM, Zhang B: The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study in elderly adults. Ann Intern Med 2005, 142:481-489.
59. Baigent C, Patrono C: Selective cyclooxygenase 2 inhibition, aspirin and cardiovascular disease a reappraisal. Arthritis Rheum 2003, 48:12-20.
60. Catella-Lawson F, Muredach PR, Kapoor SC, et al.: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001, 345:1809-1817.
61. MacDonald TM, Wei L: Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003, 306:573-574.
62. Kurth T, Glynn RJ, Walker AM, et al.: Inhibition of clinical benefit of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003, 108:1191-1195.
63. Patel TN, Goldberg KC: Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. Arch Intern Med 2004, 164:852-856.
64. Hudson M, Baron M, Rahme E, Pilote L: Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction. J Rheumatol 2005, 32:1589-1593.
65. Fischer LM, Schlienger RL, Matter CM, et al.: Current use of nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction. Pharmacotherapy 2005, 25:503-510.
66. Solomon DH, Glynn RJ, Levin R, Avorn J: Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002, 162:1099-1104.
67. Watson DJ, Rhodes T, Cai B, Guess HA: Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002, 162:1105-1110.
68. Rahme E, Pilote L, LeLorier J: Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002, 162:1111-1115.
69. Capone ML, Tacconelli S, Sciulli MG, et al.: Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004, 109:1468-1471.
70. NIH Clinical Trials. Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). http://www.clinical%20trials.gov/ct/show/NCT00007189?order=1. Accessed August 2, 2005.
71. Konstantinopoulos PA, Lehmann DF: The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding. J Clin Pharmacol 2005, 45:742-750.